The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the coronavirus disease (COVID-19) pandemic. As of August 2021, more than 200 million people have been infected with the virus and 4.3 million have lost their lives. Various monoclonal antibodies of human origin that neutralize the SARS-CoV-2 infection have been isolated from convalescent patients for therapeutic and prophylactic purposes. Several vaccines have been developed to restrict the spread of the virus and have been rapidly administered. However, the rollout of vaccines has coincided with the spread of variants of concern. Emerging variants of SARS-CoV-2 present new challenges for therapeutic antibodies and threaten the efficacy of current vaccines. Here, we review the problems faced by neutralizing antibodies and vaccines in the midst of the increasing spread of mutant viruses.

Original languageEnglish
Pages (from-to)2879-2890
Number of pages12
JournalBiochemical Society Transactions
Volume49
Issue number6
DOIs
Publication statusPublished - 2021 Dec

ASJC Scopus subject areas

  • Biochemistry

Fingerprint

Dive into the research topics of 'The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines'. Together they form a unique fingerprint.

Cite this